|
PL345241A1
(en)
|
1998-05-06 |
2001-12-03 |
Upjohn Co |
Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
|
|
JP2008500013A
(ja)
|
2003-10-03 |
2008-01-10 |
ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド |
Ｔｉｍ−３ポリペプチド
|
|
US10668119B2
(en)
|
2005-08-01 |
2020-06-02 |
Virocure, Inc. |
Attenuated reovirus
|
|
JP5368450B2
(ja)
|
2007-09-21 |
2013-12-18 |
カディラ・ヘルスケア・リミテッド |
ペプチドの高発現に適した融合タンパク質システム
|
|
CN103119054B
(zh)
|
2010-03-26 |
2017-01-18 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
|
EP2556085A2
(en)
|
2010-04-05 |
2013-02-13 |
Bar-Ilan University |
Protease-activatable pore-forming polypeptides
|
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
|
WO2012055015A1
(en)
|
2010-10-26 |
2012-05-03 |
Alberta Health Services |
Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
EP2583975A1
(en)
|
2011-10-21 |
2013-04-24 |
Heinrich-Heine-Universität Düsseldorf |
Agents and methods for the expression and secretion of peptides and proteins
|
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
|
US20150250837A1
(en)
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
BR112015007184A2
(pt)
|
2012-10-02 |
2017-08-08 |
Bristol Myers Squibb Co |
combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
|
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
US9320706B2
(en)
|
2013-03-13 |
2016-04-26 |
Transdermal Biotechnology, Inc. |
Immune modulation using peptides and other compositions
|
|
US9295647B2
(en)
|
2013-03-13 |
2016-03-29 |
Transdermal Biotechnology, Inc. |
Systems and methods for delivery of peptides
|
|
EP2792686A1
(en)
|
2013-04-17 |
2014-10-22 |
Heinrich-Heine-Universität Düsseldorf |
Methods for the expression of peptides and proteins
|
|
CN104072615B
(zh)
|
2014-01-26 |
2016-08-24 |
中国人民解放军军事医学科学院基础医学研究所 |
一种能阻断Tim-3信号通路的人Tim-3融合蛋白
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
PH12020550847A1
(en)
|
2014-02-04 |
2022-05-11 |
Incyte Corp |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
BR102014014502B1
(pt)
|
2014-06-13 |
2020-09-15 |
Ouro Fino Saúde Animal Ltda |
Vetor de expressão
|
|
DK3552615T3
(da)
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
ES2833425T3
(es)
|
2014-07-16 |
2021-06-15 |
Roussy Inst Gustave |
Combinación de virus oncolítico con moduladores de punto de control inmunitario
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
US10695426B2
(en)
|
2014-08-25 |
2020-06-30 |
Pfizer Inc. |
Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
|
|
US9710278B2
(en)
|
2014-09-30 |
2017-07-18 |
International Business Machines Corporation |
Optimizing grouping of instructions
|
|
AU2015332533B2
(en)
|
2014-10-14 |
2018-08-30 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
|
|
EP3206703B1
(en)
|
2014-10-14 |
2021-05-19 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Peptide for treating pancreatic cancer
|
|
GB201504502D0
(en)
|
2015-03-17 |
2015-04-29 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
US9957325B2
(en)
|
2015-10-13 |
2018-05-01 |
Formurex, Inc. |
Synthetic antibody mimic peptides
|
|
CN105504018B
(zh)
|
2016-01-13 |
2019-01-04 |
郑州大学 |
Lag-3亲和肽n13、制备方法及其应用
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
EP3478321A4
(en)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
|
|
US20190194324A1
(en)
|
2016-08-23 |
2019-06-27 |
The Johns Hopkins University |
THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
AU2020279371A1
(en)
|
2019-05-22 |
2021-12-23 |
Leidos, Inc. |
LAG 3 binding peptides
|
|
WO2021247789A1
(en)
|
2020-06-04 |
2021-12-09 |
Leidos, Inc. |
Immunomodulatory compounds
|